¹¬¾±°©ÊÇÍþвŮÐÔ¿µ½¡µÄÖ÷Òª¶ñÐÔÖ×ÁöÖ®Ò»¡£¡£¡£¡£¡£¡£¡£¡£Êý¾ÝÏÔʾ£¬£¬£¬£¬£¬99.7%µÄ¹¬¾±°©¶¼Óë¸ßΣÐÍHPV£¨ÈËÈéÍ·Áö²¡¶¾£©Ò»Á¬Ñ¬È¾Ïà¹Ø[1]¡£¡£¡£¡£¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬£¬ÊµÏÖÔç·ÀÔçÖΣ¬£¬£¬£¬£¬´ÓѬȾԴͷ×è¶Ï°©±äÀú³Ì£¬£¬£¬£¬£¬ÒѳÉΪ·À¿ØµÄÒªº¦¡£¡£¡£¡£¡£¡£¡£¡£HPVÐͱð¶àÑù£¬£¬£¬£¬£¬¾ÙÐо«×¼·ÖÐͼì²â£¬£¬£¬£¬£¬Ã÷ȷѬȾµÄÏêϸÐͱ𣬣¬£¬£¬£¬²Å»ªÊµÏÖÕæÕýÒâÒåÉϵÄÔç·¢Ã÷¡¢Ôç¸ÉÔ¤£¬£¬£¬£¬£¬Îª·ÀÖÎÌṩ¿ÆÑ§ÒÀ¾Ý£¬£¬£¬£¬£¬ÇÐÊµÊØ»¤Å®ÐÔ¿µ½¡¡£¡£¡£¡£¡£¡£¡£¡£

ÈÏÇåHPV¼Ò×壬£¬£¬£¬£¬Ðͱð¾öÒéΣº¦
HPVÊÇÒ»¸ö°üÀ¨200¶àÖÖÐͱðµÄÅÓ¸÷ÈË×å¡£¡£¡£¡£¡£¡£¡£¡£Æ¾Ö¤ÆäÖ°©Ç±Á¦£¬£¬£¬£¬£¬¿É·ÖΪ¶þ´óÀà[2]£º
¸ß/ÖÐΣÐÍHPV£ºÓë99.7%µÄ¹¬¾±°©Ïà¹Ø£¬£¬£¬£¬£¬Êǵ¼Ö¹¬¾±°©¡¢ÒõµÀ°©¡¢¸ØÃŰ©µÈ¶ñÐÔÖ×ÁöµÄÖ÷ÒªÔªÐ×£¬£¬£¬£¬£¬±ØÐèÑÏɸÑÏ¿Ø[1]¡£¡£¡£¡£¡£¡£¡£¡£
µÍΣÐÍHPV£ºËäÓë°©Ö¢¹ØÏµ²»´ó£¬£¬£¬£¬£¬È´ÊÇÆ¤·ôðàºÍÉúÖ³Æ÷ðࣨÈç¼âÈñʪðࣩµÄ¡°×ï¿ý×ï¿ý¡±£¬£¬£¬£¬£¬ÆäѬȾÐÔÇ¿¡¢Ò×ÖØ¸´±¬·¢£¬£¬£¬£¬£¬¸ø»¼Õß´øÀ´ÉíÐÄË«ÖØÀ§ÈÅ¡£¡£¡£¡£¡£¡£¡£¡£
Ö»¼ì²â¸ßΣÐÍHPV£¬£¬£¬£¬£¬ÎÞ·¨ÆÀ¹ÀÓëµÍΣÐÍHPVÏà¹ØµÄ¼²²¡¡£¡£¡£¡£¡£¡£¡£¡£Òò´Ë£¬£¬£¬£¬£¬Ò»´Î²ÉÑùͬʱ¾ÙÐÐÆéá«Î£ÑÇÐͼì²â£¬£¬£¬£¬£¬ÁýÕÖÐͱðÔ½¶à£¬£¬£¬£¬£¬Ô½Çå¾²¡£¡£¡£¡£¡£¡£¡£¡£
ȨÍþÖ¸ÄÏÍÆ¼ö£ºHPVºËËá¼ì²âÊǹ¬¾±°©³õɸÊ×ѡҪÁì
ÌìÏÂÎÀÉú×éÖ¯£¨WHO£©¼°º£ÄڶಿȨÍþÖ¸ÄÏÃ÷È·ÍÆ¼ö£ºHPVºËËá¼ì²âΪ¹¬¾±°©³õɸÊ×ѡҪÁì[3-6]£¬£¬£¬£¬£¬ÆäѸËٶȸü¸ß¡¢Ð§¹û¸ü¿É¿¿¡£¡£¡£¡£¡£¡£¡£¡£Í¨¹ý¾«×¼·ÖÁ÷£¬£¬£¬£¬£¬¿Éɸѡ³ö¸ßΣº¦ÈËȺ£¬£¬£¬£¬£¬ÊµÏÖ¸öÐÔ»¯¾«×¼Ò½ÁÆ¡£¡£¡£¡£¡£¡£¡£¡£

2121·Ç·²HPV 31·ÖÐͼì²â Ò»´Î²ÉÑù£¬£¬£¬£¬£¬Ë«ÖØÊØ»¤
2121·Ç·²HPV 31·ÖÐͺËËá¼ì²â½ÓÄɶàÖØÌ½ÕëÀ©Ôö£¨MPA£©ÊÖÒÕ£¬£¬£¬£¬£¬Í»ÆÆ¹Å°åPCRÊÖÒյľÖÏÞ£¬£¬£¬£¬£¬µ¥¹ÜÑù±¾¼´¿ÉʵÏÖ31ÖÖ³£¼ûHPVÐͱðµÄ¾«×¼·ÖÐÍ¡£¡£¡£¡£¡£¡£¡£¡£
ʶ±ð18ÖÖ¸ß/ÖÐΣÐÍHPV£¬£¬£¬£¬£¬ÍêÕûÁýÕÖWHO¡¢¹ú¼ÒÎÀ½¡Î¯ÒªÇ󱨲éµÄËùÓиßΣÐͱ𣬣¬£¬£¬£¬ÖúÁ¦¾¡Ôç·¢Ã÷¹¬¾±°©±¬·¢Î£º¦¡£¡£¡£¡£¡£¡£¡£¡£
ʶ±ð13ÖÖµÍΣÐÍHPV£¬£¬£¬£¬£¬Ã÷È·¿ÉÒý·¢¼âÈñʪðࡢƤ·ôðàµÄµÍΣÐͱ𡣡£¡£¡£¡£¡£¡£¡£
Ò»´Î²ÉÑù¡¢Ò»´Î¼ì²â£¬£¬£¬£¬£¬¼´¿ÉͬʱÍê³É·À°©É¸²éÓë·Àðà¼à²â¡£¡£¡£¡£¡£¡£¡£¡£

½¨Òéɸ²éÈËȺ
¡¶Öйú×Ó¹¬¾±°©É¸²éÖ¸ÄÏ£¨2023°æ£©¡·µÈר¼Ò¹²Ê¶£¬£¬£¬£¬£¬ÒÔ¼°WHO¡¢ASCCP£¨ÃÀ¹úÒõµÀ¾µºÍ¹¬¾±²¡Àíѧ»á£©µÈ¹ú¼Êרҵ»ú¹¹£¬£¬£¬£¬£¬ÍƼöÒÔÏÂÈËȺ°´ÆÚ¾ÙÐÐHPVɸ²é£º
? 25-65ËêÅ®ÐÔ£º¹¬¾±°©É¸¿¼½¹µãÈËȺ£¬£¬£¬£¬£¬Ðè°´ÆÚ¾ÙÐÐHPV¼ì²âÍŽáϸ°ûѧ¼ì²é¡£¡£¡£¡£¡£¡£¡£¡£
? ÓÐÐÔÉúÑÄÊ·µÄÅ®ÐÔ£ºÎÞÂÛÄêË꣬£¬£¬£¬£¬Ö»Òª×îÏÈÐÔÉúÑļ´±£´æÑ¬È¾Î£º¦£¬£¬£¬£¬£¬½¨Ò龡ÔçÆô¶¯É¸²é¡£¡£¡£¡£¡£¡£¡£¡£
? ÓмÈÍù¹¬¾±²¡±ä/¹¬¾±°©ÖÎÁÆÊ·ÈËȺ£ºÊõºóÐèºã¾ÃËæ·Ã¼à²â£¬£¬£¬£¬£¬±ÜÃ⸴·¢¡£¡£¡£¡£¡£¡£¡£¡£
? HPVÒßÃç½ÓÖÖºóÈËȺ£º½ÓÖÖºóÈÔÐè°´Ö¸ÄÏɸ²é£¬£¬£¬£¬£¬ÆÀ¹ÀÒßÃç±£»£»£»£»£»£»¤Ð§¹û²¢ÁýÕÖδ±£»£»£»£»£»£»¤Ðͱ𡣡£¡£¡£¡£¡£¡£¡£
? ÐÔ»îÔ¾ÈËȺ£¨º¬ÄÐÐÔ£©£ºÄÐÐÔ¿É×÷ΪѬȾԴ£¬£¬£¬£¬£¬Ò²¿É±¬·¢¸ØÃŰ©¡¢Òõ¾¥°©µÈ£¬£¬£¬£¬£¬½¨ÒéÅäºÏɸ²é¡£¡£¡£¡£¡£¡£¡£¡£
? ÃâÒß¹¦Ð§µÍÏÂÕߣºÈçHIVѬȾ¡¢Æ÷¹ÙÒÆÖ²Êõºó¡¢ºã¾ÃʹÓü¤ËصÈÃâÒßȱÏÝÕߣ¬£¬£¬£¬£¬ÕâÀàÈËȺµÄѬȾɨ³ýÄÜÁ¦Èõ£¬£¬£¬£¬£¬Ðè¸ßƵ¼à²â¡£¡£¡£¡£¡£¡£¡£¡£
ÒÔÈ«ÖÜÆÚÊØ»¤ ʵÏÖ´ÓÖβ¡µ½·À°©µÄ×Ô¶¯¿çÔ½
2121·Ç·²½«HPV·À¿ØÉî¶ÈÈÚÈëÅ®ÐÔÈ«ÉúÃüÖÜÆÚ¿µ½¡¹ÜÀí£¬£¬£¬£¬£¬ÒÀÍÐ18Äê¼ÓÈ빬¾±°©·ÀÖι«ÒæÐж¯µÄ³õÐÄÓë¡°µÏÁ«»¨¡±Ðж¯µÄÒ»Á¬»ýµí£¬£¬£¬£¬£¬Í¨¹ýÈں϶àÊÖÒÕÆ½Ì¨µÄ¾«×¼¼ì²â·þÎñ£¬£¬£¬£¬£¬¹¹½¨Å®ÐÔ¿µ½¡Î£º¦ÆÀ¹Àϵͳ£¬£¬£¬£¬£¬½«¿µ½¡ÊØ»¤¹Ø¿Ú´Ó¡°Ê¶°©±æ²¡¡±Ç°Öõ½¡°¿ÆÑ§¸ÉÔ¤¡±£¬£¬£¬£¬£¬ÒÔרҵ¸³ÄÜÅ®ÐÔÕÆ¿Ø¿µ½¡×Ô¶¯È¨£¬£¬£¬£¬£¬ÖþÀÎÈ«ÖÜÆÚ·À»¤ÆÁÕÏ¡£¡£¡£¡£¡£¡£¡£¡£

²Î¿¼ÎÄÏ×
[1] Andersson S, Safari H, Mints M, et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN)[J]. Br J Cancer, 2005, 92(12): 2195-2200.
[2] ÀîÃ÷Öé,ÕÔ·½»Ô,ÒüÈçÌú,µÈ.Ô¤·ÀÐÔÈËÈéÍ·Áö²¡¶¾ÒßÃçÖйúÁÙ´²Ó¦ÓÃÖ¸ÄÏ£¨2025°æ£©[J].Öйú°¬×̲¡ÐÔ²¡,2025,31(07):784-798.DOI:10.13419/j.cnki.aids.2025.07.18.
[3] WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
[4] ÀîÃ÷Öé,κÀö»Ý,ËåÁú,µÈ.Öйú×Ó¹¬¾±°©É¸²éÖ¸ÄÏ£¨Ò»£©[J].Öйú¸¾²ú¿ÆÁÙ´²ÔÓÖ¾,2023,24(04):437-442.DOI:10.13390/j.issn.1672-1861.2023.04.029.
[5] ËÎÓñÀö,À÷,µËÀ×,µÈ.»ùÓÚÁÙ´²ÐèÇóµÄ¹¬¾±°©»ùÒò¼ì²â¹æ·¶»¯Ñ¡ÔñÖйúר¼Ò¹²Ê¶£¨2025Äê°æ£©[J].Ö×ÁöѧÔÓÖ¾,2025,31(07):557-566.
[6] ³ÂÍòÇà,ÐìÖ¾¼á,ÔøÇ¿,µÈ.¿µ½¡Ìå¼ì»ú¹¹·À°©Ìå¼ìÖ¸ÄÏ£¨2025Äê°æ£©[J].ÖйúÖ×Áö,2025,34(09):667-697.
[7] ÖлªÒ½Ñ§»áƤ·ôÐÔ²¡Ñ§·Ö»á,ÖйúÒ½Ê¦Ð»áÆ¤·ô¿ÆÒ½Ê¦·Ö»á,Öйú¿µ¸´Ò½Ñ§»áƤ·ôÐÔ²¡Î¯Ô±»á.Öйú¼âÈñʪðàÁÙ´²ÕïÁÆÖ¸ÄÏ(2021ÍêÕû°æ)[J].ÖйúƤ·ôÐÔ²¡Ñ§ÔÓÖ¾,2021,35(04):359-374.